Rates of long-term treatment discontinuation were low among patients with ankylosing spondylitis receiving first-line anti-TNF therapy for at least 2 years.
The global ankylosing spondylitis treatment market is witnessing significant growth, with projections indicating a market value of USD 8.06 billion in 2022 and an expected increase to USD 5.1409 ...
Background: Observational studies have shown an increased risk of ocular inflammatory diseases in patients with ankylosing spondylitis (AS), but the genetically predicted association remains unclear.
Johnson & Johnson’s portfolio now includes treatment options for patients with rheumatoid arthritis, axial spondylarthritis, and polyarticular juvenile idiopathic arthritis.High Wycombe, UK, 17 ...
A Center Township man and his wife have filed a lawsuit claiming a yearslong delay in diagnosing his kidney disease led to him developing irreversible end state renal disease. Chad and Michelle Kuzar ...
While treatment with CZP significantly reduced inflammation among patients with active axSpA, this did not always translate into marked clinical improvements.